PapersFlow Research Brief
Lymphoma Diagnosis and Treatment
Research Guide
What is Lymphoma Diagnosis and Treatment?
Lymphoma diagnosis and treatment is the evidence-based process of classifying lymphoid neoplasms using standardized pathology, molecular profiling, and imaging-based staging to select and evaluate therapies such as immunochemotherapy and risk-adapted regimens.
The modern diagnostic backbone for lymphoma is disease classification, which is codified in “The 2016 revision of the World Health Organization classification of lymphoid neoplasms” (2016) and historically grounded in “A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]” (1994). Response assessment and staging are standardized in “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification” (2014), which formalized contemporary evaluation and follow-up expectations for Hodgkin and non-Hodgkin lymphoma. The provided corpus contains 129,866 works on lymphoma diagnosis and treatment, indicating a large and mature research literature (5-year growth rate: N/A).
Topic Hierarchy
Research Sub-Topics
Diffuse Large B-Cell Lymphoma Classification
This sub-topic examines gene expression profiling and molecular subtypes such as germinal center B-cell-like and activated B-cell-like DLBCL to refine diagnostic classification. Researchers study immunohistochemical algorithms and next-generation sequencing for precise categorization and prognosis prediction.
Rituximab in Non-Hodgkin Lymphoma Therapy
This sub-topic investigates the integration of rituximab with chemotherapy regimens like R-CHOP and its impact on elderly patients with NHL. Researchers analyze response rates, toxicity profiles, and long-term survival benefits from randomized clinical trials.
Hodgkin Lymphoma PET Imaging
This sub-topic focuses on FDG-PET for staging, interim response assessment, and end-of-treatment evaluation in Hodgkin lymphoma per Lugano criteria. Researchers develop quantitative metrics like Deauville score to guide therapy de-escalation and predict relapse.
Follicular Lymphoma Genetic Pathogenesis
This sub-topic explores t(14;18) translocation involving BCL2 and additional mutations in epigenetic regulators driving follicular lymphoma progression. Researchers investigate clonal evolution and transformation to aggressive disease using whole-genome sequencing.
Mantle Cell Lymphoma Prognostication
This sub-topic covers MIPI scoring systems, TP53 mutations, and SOX11 expression for risk stratification in mantle cell lymphoma. Researchers validate biomarkers to predict response to intensive regimens like hyper-CVAD or autologous transplant.
Why It Matters
Accurate lymphoma diagnosis directly determines therapy selection and prognosis because distinct biological entities respond differently to the same regimen. For example, “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling” (2000) demonstrated that diffuse large B-cell lymphoma (DLBCL) comprises distinct molecular types identifiable by gene expression profiling, establishing a rationale for biologically informed stratification rather than treating DLBCL as a single uniform disease. On the treatment side, Coiffier et al. (2002) reported in “CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma” that adding rituximab to CHOP increased the complete-response rate and prolonged event-free and overall survival in elderly patients with DLBCL, without a clinically significant increase in toxicity—an example where a diagnostic label (DLBCL) and a defined regimen (R-CHOP vs CHOP) translate into measurable patient benefit. Prognostication also affects real-world decisions such as eligibility for intensified therapy or clinical trials: “A Predictive Model for Aggressive Non-Hodgkin's Lymphoma” (1993) specified that the international index and the age-adjusted international index should be used to design therapeutic trials and select appropriate therapeutic approaches for individual patients. Standardized staging and response criteria in Cheson et al. (2014) support comparability across studies and clinical sites, enabling consistent interpretation of imaging and clinical endpoints when deciding whether to continue, change, or stop therapy.
Reading Guide
Where to Start
Start with Cheson et al. (2014) “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification” because it provides a practical, standardized structure for baseline evaluation, staging, and response assessment that underpins both clinical care and trial reporting.
Key Papers Explained
For disease definition, Harris et al. (1994) “A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]” established a standard clinicopathologic taxonomy that is updated and consolidated in Swerdlow et al. (2016) “The 2016 revision of the World Health Organization classification of lymphoid neoplasms.” For biologic stratification within a major entity, Alizadeh et al. (2000) “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling” provides a molecular framework that complements morphology-based classification. For treatment evidence in a common aggressive lymphoma, Coiffier et al. (2002) “CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma” links diagnosis to regimen choice and clinical outcomes. For prognosis and research planning, “A Predictive Model for Aggressive Non-Hodgkin's Lymphoma” (1993) specifies indices intended for both trial design and individualized therapeutic approaches, while Peto et al. (1977) supports rigorous analysis of time-to-event outcomes in trials requiring prolonged observation.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
A current frontier is tighter integration of standardized classification (Swerdlow et al. (2016)) with molecular subgrouping (Alizadeh et al. (2000)) so that staging and response frameworks (Cheson et al. (2014)) remain interpretable across increasingly heterogeneous biologic risk groups. Another active direction is optimizing trial design and endpoint analysis for long follow-up and changing standards of care, drawing on methods described by Peto et al. (1977), while maintaining comparability to established immunochemotherapy benchmarks such as Coiffier et al. (2002).
Papers at a Glance
In the News
Current Grant Opportunities
The Lymphoma Research Foundation announces Requests for Proposals (RFPs) on a regular basis each year. In calendar year 2025, the Foundation will offer its 2026 Early Career Grant programs; the Cli...
Ontario Fast-Tracking Access to Six Breakthrough Cancer Drugs
Ontario Newsroom
BREYANZI
* Adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B‑cell lymph...
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
Adding blinatumomab to combination chemotherapy in patients with newly diagnosed childhood standard-risk B-cell ALL of average or higher risk of relapse significantly improved disease-free survival...
Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database
Shadman, M., Harper, J.S., Bokun, A. _et al._ Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database.
Code & Tools
The MLL Munich Leukemia Laboratory is a leading national and international laboratory for the diagnosis and research of leukemia and lymphoma – and...
**Note: The analysis was developed for DLBCL only** The analysis workflow is presented in the diagram below, highlighting the main steps and logica...
This repository provides the official implementation of paper titled "Artificial Intelligence-based Assessment of PD-L1 Expression in Diffuse Large...
Human T-lymphotrophic virus 1 (HTLV-1) is the causative agent for adult T-cell leukemia/lymphoma (ATL) and many other human diseases. Accurate and ...
## Repository files navigation # OncoAct This repository contains the suite of algorithms used in the Hartwig Medical Foundation OncoAct pipeline
Recent Preprints
SEOM–GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025)
## Diagnosis, pathology, and molecular biology
Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology
findings provide a valuable framework for clinicians and policymakers to optimize lymphoma management, balancing innovation with the allocation of resources and clinical feasibility. KEYWORDS lymph...
Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up - The European Hematology Association (EHA)
* Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up Read the full guideline in HemaSphere ## Full title Large B-cell lymphoma (LBCL): EHA Clin...
Diagnostic and therapeutic pathways for lymphoma patients
allocation of resources and clinical feasibility. Keywords: lymphoma diagnosis and treatment, NGT, Delphi consensus, advanced molecular diagnostics, multidisciplinary cancer care, immunotherapy, CA...
Real-world treatment patterns and clinical outcomes ...
Treatment options for diffuse large B-cell lymphoma (DLBCL) have expanded, but real-world data on treatment patterns and outcomes remain limited. This study examined real-world outcomes in DLBCL pa...
Latest Developments
Recent developments in lymphoma diagnosis and treatment research as of February 2026 include the evaluation of novel therapies such as venetoclax combined with chemotherapy for high-grade B-cell lymphomas (UCSF), and promising results from new treatment combinations showing over 90% complete response rates for early-stage Hodgkin lymphoma (MD Anderson). Additionally, there are ongoing clinical trials exploring targeted therapies like mosunetuzumab, glofitamab, and ATG-031, as well as innovative approaches such as immune-targeting vaccines like NOUS-209 for Lynch Syndrome patients (UCSF, MD Anderson). Advances are also being guided by updated clinical guidelines, such as the SEOM–GOTEL update on diffuse large B-cell lymphoma (Springer), and new efficacy data from phase 2 trials of therapies like odronextamab, axicabtagene ciloleucel, and zuma-14, reflecting a focus on personalized, targeted, and immunotherapy-based approaches (Nature, Nature).
Sources
Frequently Asked Questions
What is the current standard framework for classifying lymphoma entities in clinical practice and research?
A widely used contemporary framework is provided by Swerdlow et al. (2016) in “The 2016 revision of the World Health Organization classification of lymphoid neoplasms,” which reflects consensus updates to recognized entities and their defining features. A foundational predecessor is Harris et al. (1994) “A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments],” which helped standardize clinicopathologic categories used for diagnosis and study design.
How are initial evaluation, staging, and response assessment standardized for Hodgkin and non-Hodgkin lymphoma?
Cheson et al. (2014) “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification” modernized recommendations for evaluation, staging, and response assessment for HL and NHL. The Lugano framework is used to harmonize baseline workup and define response categories so that treatment decisions and trial endpoints are comparable across centers.
How did gene expression profiling change the understanding of diffuse large B-cell lymphoma?
Alizadeh et al. (2000) showed in “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling” that DLBCL includes distinct types that can be identified by gene expression patterns. This finding supports the diagnostic principle that molecular profiling can define clinically relevant subgroups rather than relying only on morphology.
Which evidence supports adding rituximab to CHOP for elderly patients with diffuse large B-cell lymphoma?
Coiffier et al. (2002) demonstrated in “CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma” that rituximab plus CHOP increases the complete-response rate and prolongs event-free and overall survival in elderly DLBCL patients. The same study reported no clinically significant increase in toxicity with the addition of rituximab.
Which prognostic model is explicitly recommended for trial design and therapy selection in aggressive non-Hodgkin lymphoma?
“A Predictive Model for Aggressive Non-Hodgkin's Lymphoma” (1993) stated that the international index and the age-adjusted international index should be used in the design of future therapeutic trials and in selecting appropriate therapeutic approaches for individual patients. This establishes a direct link between baseline risk stratification and both clinical decision-making and research methodology.
Which statistical and trial-analysis references are commonly used when analyzing lymphoma outcomes in prolonged follow-up studies?
Peto et al. (1977) in “Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples” provides methodological guidance for trials where endpoints require long observation. Kanda (2012) in “Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics” describes a practical software approach used for medical statistical analyses, which is relevant when implementing standard survival and response analyses reported in lymphoma studies.
Open Research Questions
- ? How can molecular subtypes defined in “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling” (2000) be operationalized into routine diagnostic workflows that remain consistent with entity definitions in “The 2016 revision of the World Health Organization classification of lymphoid neoplasms” (2016)?
- ? Which response-assessment rules in “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification” (2014) most strongly predict long-term outcomes when applied to biologically distinct lymphoma subtypes?
- ? How should prognostic indices described in “A Predictive Model for Aggressive Non-Hodgkin's Lymphoma” (1993) be integrated with modern molecular profiling signals (as in Alizadeh et al. (2000)) to improve individualized treatment selection?
- ? What trial designs and statistical approaches from Peto et al. (1977) best accommodate evolving standards of care (e.g., immunochemotherapy) while preserving interpretability across prolonged follow-up?
- ? In DLBCL, which patient subsets derive the greatest incremental benefit from adding rituximab to CHOP as established in Coiffier et al. (2002), and how should those subsets be defined using standardized classification and staging systems?
Recent Trends
The provided dataset indicates a very large literature base (129,866 works) organized around classification, molecular profiling, genetic pathogenesis, PET-based assessment, and rituximab-containing therapy, with growth over 5 years listed as N/A. Within the most-cited core, emphasis has shifted from purely morphologic categories toward consensus entity definitions (“The 2016 revision of the World Health Organization classification of lymphoid neoplasms” ) and standardized response frameworks (“Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification” (2014)).
2016In parallel, biologic stratification remains anchored by Alizadeh et al. and therapeutic benchmarking by Coiffier et al. (2002), reinforcing a research trajectory that links molecular subtyping and standardized staging to regimen selection and outcome evaluation.
2000Research Lymphoma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lymphoma Diagnosis and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers